KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cash & Equivalents (2016 - 2025)

Biomarin Pharmaceutical's Cash & Equivalents history spans 17 years, with the latest figure at $1.3 billion for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 39.12% year-over-year to $1.3 billion, compared with a TTM value of $1.3 billion through Dec 2025, up 39.12%, and an annual FY2025 reading of $1.3 billion, up 39.12% over the prior year.
  • Cash & Equivalents for Q4 2025 was $1.3 billion at Biomarin Pharmaceutical, up from $1.3 billion in the prior quarter.
  • The five-year high for Cash & Equivalents was $1.3 billion in Q4 2025, with the low at $580.1 million in Q1 2023.
  • Average Cash & Equivalents over 5 years is $810.1 million, with a median of $735.8 million recorded in 2022.
  • Year-over-year, Cash & Equivalents crashed 39.24% in 2021 and then soared 85.08% in 2025.
  • Tracing BMRN's Cash & Equivalents over 5 years: stood at $587.3 million in 2021, then rose by 23.37% to $724.5 million in 2022, then grew by 4.22% to $755.1 million in 2023, then increased by 24.86% to $942.8 million in 2024, then soared by 39.12% to $1.3 billion in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Cash & Equivalents are $1.3 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.2 billion (Q2 2025).